KOIOS MEDICAL, INC
OperatingKoios Medical, Inc.
Healthcare · New York, NY · Founded 2011
AI-powered software diagnosing cancer. Super human accuracy
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
12 people
Healthcare Visionary. Co-founded medical software company acquired by Stryker. 25+ years advising Fortune 500 clients including Humana. Ex-Arthur Andersen Senior Manager. Now leads Newsweek's 'World's Best Digital Health Company.' Northwestern MBA.
AI Pioneer. Designed facial recognition systems for US DoD. Pivoted to medical imaging. Published X peer-reviewed medical imaging research. Oversees Koios R&D developing algorithms trained on 500,000+ ultrasound images
AI Veteran. Designed enterprise facial recognition systems & commercial SDKs. Led Koios to HuffPost's '10 AI Health Companies to Follow.' 4-year varsity athlete (Captain). Rutgers University Engineering BS (Honors). DSP specialist.
VC Veteran. Structured deals across healthcare IT, specialty pharmaceuticals & consumer products. Corporate board experience includes Audit, Compensation & Governance Committees. Corp dev, enterprise sales expertise. CFA Charterholder. Yale Law School JD.
Software Veteran. 20+ years designing & delivering radiology software. Director at Intelerad Medical Systems (acquired by GE HealthCare for $2.3B), serving 1,500+ healthcare organizations globally, including 41 of top 100 U.S. radiology groups.
Diagnostic Innovator. Led research proving AI boosts cancer detection 14%, reduces false positives 35%. Multiple FDA clearances. UPenn and Memorial Sloan Kettering published research. Rutgers BS and MD; Princeton Quantitative Molecular Biology PhD.
Imaging Master. 20+ years at RadNet (largest U.S. outpatient imaging provider, 400+ centers). Launched PET/CT, PET/MR & Nuclear Medicine programs. Led largest international cancer-screening partnership in Middle East. UC San Diego Nuclear Medicine.
Revenue Driver. 25+ years building top-performing sales and revenue growth teams. Focus on radiology and AI solutions for oncology and women’s health. Former SVP at iCAD. Led teams at Tempus, Volpara, Xoft. Clarkson University Mechanical Engineering BS.
Sonography Specialist. Registered Diagnostic Medical Sonographer/Ultrasound Technologist. Trained 100+ healthcare facilities to improve diagnostic accuracy in lesion categorization.
Show 3 more peopleShow fewer
Clinical Technologist. 20+ years at Vanderbilt Medical Center & Saint Thomas Health in breast imaging. Specialist at Perimeter Medical Imaging AI teaching optical coherence tomography to surgeons. RT(R)(M)(BS), ARRT certified.
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 15 filings on EDGAR- Form C/AAug 21, 20260001764417-26-000006EDGAR
- Form C/AApr 29, 20260001764417-26-000004EDGAR
- Form C-ARApr 28, 20260001764417-26-000002EDGAR
- Form C/AJan 21, 20260001764417-26-000001EDGAR
- Form DDec 23, 20250001764417-25-000003EDGAR
- Form CDec 17, 20250001764417-25-000002EDGAR
- Form C-ARApr 25, 20250001670254-25-000428EDGAR
- Form D/AJun 24, 20240001764417-24-000003EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.